Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

The importance of sexuality, changes in erectile functioning and its association with self-esteem in men with localized prostate cancer: data from an observational study.

Hilger C, Schostak M, Neubauer S, Magheli A, Fydrich T, Burkert S, Kendel F.

BMC Urol. 2019 Jan 21;19(1):9. doi: 10.1186/s12894-019-0436-x.

2.

Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis.

George DJ, Martini JF, Staehler M, Motzer RJ, Magheli A, Donskov F, Escudier B, Li S, Casey M, Valota O, Laguerre B, Pantuck AJ, Pandha HS, Patel A, Lechuga M, Ravaud A.

Clin Cancer Res. 2018 Nov 6. doi: 10.1158/1078-0432.CCR-18-1724. [Epub ahead of print]

PMID:
30401688
3.

Influences of Surgical Volume on Perioperative and Oncological Outcomes Following Radical Prostatectomy.

Pohle M, Magheli A, Fischer T, Ralla B, Miller K, Hinz S.

Urol Int. 2018;101(3):256-262. doi: 10.1159/000492119. Epub 2018 Sep 25.

PMID:
30253389
4.

Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib.

Rini BI, Escudier B, Martini JF, Magheli A, Svedman C, Lopatin M, Knezevic D, Goddard AD, Febbo PG, Li R, Lin X, Valota O, Staehler M, Motzer RJ, Ravaud A.

Clin Cancer Res. 2018 Sep 15;24(18):4407-4415. doi: 10.1158/1078-0432.CCR-18-0323. Epub 2018 May 17.

PMID:
29773662
5.

Intermittent vs continuous docetaxel therapy in patients with metastatic castration-resistant prostate cancer - a phase III study (PRINCE).

Cash H, Steiner U, Heidenreich A, Klotz T, Albers P, Melchior S, Martus P, Fuller F, Magheli A, Hinz S, Kempkensteffen C, Miller K; PRINCE investigators.

BJU Int. 2018 Nov;122(5):774-782. doi: 10.1111/bju.14239. Epub 2018 May 6.

PMID:
29633515
6.

Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study.

George DJ, Martini JF, Staehler M, Motzer RJ, Magheli A, Escudier B, Gerletti P, Li S, Casey M, Laguerre B, Pandha HS, Pantuck AJ, Patel A, Lechuga MJ, Ravaud A.

Clin Cancer Res. 2018 Apr 1;24(7):1554-1561. doi: 10.1158/1078-0432.CCR-17-2822. Epub 2018 Jan 26.

PMID:
29374054
7.

[A retrospective analysis of functional and oncologic outcomes following surgical treatment of patients with pT1/pT2 renal cell carcinoma at a tertiary referral centre].

Ralla B, Buhl S, Goranova I, Maxeiner A, Friedersdorff F, Magheli A, Hinz S, Fuller TF, Miller K, Busch J.

Aktuelle Urol. 2017 Dec 19. doi: 10.1055/s-0043-118799. [Epub ahead of print] German.

PMID:
29258130
8.

Complications, functional and quality of life outcomes following primary and secondary implantation of penile prosthesis at a tertiary referral center.

Ralla B, Goranova I, Börnstein N, Friedersdorff F, Maxeiner A, Magheli A, Hinz S, Neymeyer J, Miller K, Busch J.

Int J Impot Res. 2018 Apr;30(2):49-53. doi: 10.1038/s41443-017-0005-3. Epub 2017 Dec 4.

PMID:
29203844
9.

[The use of partial nephrectomy in the treatment of patients with pT1/pT2 renal cell carcinoma: a trend analysis from a tertiary referral centre].

Ralla B, Buhl S, Goranova I, Pohle M, Maxeiner A, Friedersdorff F, Magheli A, Hinz S, Fuller TF, Miller K, Busch J.

Aktuelle Urol. 2018 Jun;49(3):250-255. doi: 10.1055/s-0043-118791. Epub 2017 Nov 16. German.

PMID:
29145686
10.

Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.

Motzer RJ, Ravaud A, Patard JJ, Pandha HS, George DJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Casey M, Serfass L, Pantuck AJ, Staehler M.

Eur Urol. 2018 Jan;73(1):62-68. doi: 10.1016/j.eururo.2017.09.008. Epub 2017 Sep 28.

PMID:
28967554
11.

The Effect of Evolving Strategies in the Surgical Management of Organ-Confined Prostate Cancer: Comparison of Data from 2005 to 2014 in a Multicenter Setting.

Pohle M, Magheli A, Fischer T, Kempkensteffen C, Busch J, Cash H, Miller K, Hinz S.

Adv Ther. 2017 Feb;34(2):576-585. doi: 10.1007/s12325-016-0469-4. Epub 2017 Jan 4.

12.

Significant reduction in positive surgical margin rate after laparoscopic radical prostatectomy by application of the modified surgical margin recommendations of the 2009 International Society of Urological Pathology consensus.

Maxeiner A, Magheli A, Jöhrens K, Kilic E, Braun TL, Kempkensteffen C, Hinz S, Stephan C, Miller K, Busch J.

BJU Int. 2016 Nov;118(5):750-757. doi: 10.1111/bju.13451. Epub 2016 Mar 19.

13.

Prevalence of Late-Onset Hypogonadism in Men with Localized and Metastatic Renal Cell Carcinoma.

Ralla B, Magheli A, Wolff I, Erber B, Goranova I, Friedersdorff F, Hinz S, Kempkensteffen C, Miller K, Busch J.

Urol Int. 2017;98(2):191-197. doi: 10.1159/000450652. Epub 2016 Oct 13.

PMID:
27732978
14.

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.

Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Martini JF, Ramaswamy K, Casey M, Staehler M, Patard JJ; S-TRAC Investigators.

N Engl J Med. 2016 Dec 8;375(23):2246-2254. Epub 2016 Oct 9.

15.

Vasopressin lowers renal epoxyeicosatrienoic acid levels by activating soluble epoxide hydrolase.

Boldt C, Röschel T, Himmerkus N, Plain A, Bleich M, Labes R, Blum M, Krause H, Magheli A, Giesecke T, Mutig K, Rothe M, Weldon SM, Dragun D, Schunck WH, Bachmann S, Paliege A.

Am J Physiol Renal Physiol. 2016 Dec 1;311(6):F1198-F1210. doi: 10.1152/ajprenal.00062.2016. Epub 2016 Sep 28.

16.

Long-Term Donor Outcomes after Pure Laparoscopic versus Open Living Donor Nephrectomy: Focus on Pregnancy Rates, Hypertension and Quality of Life.

Friedersdorff F, Kothmann L, Manus P, Roigas J, Kempkensteffen C, Magheli A, Busch J, Liefeldt L, Giessing M, Deger S, Schostak M, Miller K, Fuller TF.

Urol Int. 2016;97(4):450-456. Epub 2016 Aug 30.

17.

Retrospective Analysis of Fifth-Line Targeted Therapy Efficacy in Patients with Metastatic Renal Cell Carcinoma.

Ralla B, Erber B, Goranova I, Klooker A, Maxeiner A, Hinz S, Kempkensteffen C, Magheli A, Miller K, Busch J.

Urol Int. 2017;98(2):184-190. doi: 10.1159/000444764. Epub 2016 Mar 11.

PMID:
26963286
18.

Efficacy of fourth-line targeted therapy in patients with metastatic renal cell carcinoma: a retrospective analysis.

Ralla B, Erber B, Goranova I, von der Aue L, Floercken A, Hinz S, Kempkensteffen C, Magheli A, Miller K, Busch J.

World J Urol. 2016 Aug;34(8):1147-54. doi: 10.1007/s00345-015-1740-z. Epub 2015 Dec 16.

PMID:
26676614
19.

Dysfunction of PSA-specific CD8+ T cells in prostate cancer patients correlates with CD38 and Tim-3 expression.

Japp AS, Kursunel MA, Meier S, Mälzer JN, Li X, Rahman NA, Jekabsons W, Krause H, Magheli A, Klopf C, Thiel A, Frentsch M.

Cancer Immunol Immunother. 2015 Nov;64(11):1487-94. doi: 10.1007/s00262-015-1752-y. Epub 2015 Aug 20.

PMID:
26289091
20.

Optimizing scintigraphic evaluation of split renal function in living kidney donors using the geometric mean method: a preliminary retrospective study.

Weinberger S, Baeder M, Scheurig-Muenkler C, Steffen IG, Magheli A, Miller K, Kempkensteffen C.

J Nephrol. 2016 Jun;29(3):435-441. doi: 10.1007/s40620-015-0223-z. Epub 2015 Aug 19.

PMID:
26286903
21.

[Propensity score comparison of the various radical surgical techniques for high-risk prostate cancer].

Busch J, Gonzalgo M, Leva N, Ferrari M, Friedersdorff F, Hinz S, Kempkensteffen C, Miller K, Magheli A.

Aktuelle Urol. 2015 Jan;46(1):45-51. doi: 10.1055/s-0034-1395562. Epub 2014 Dec 19. German.

PMID:
25526221
22.

Staging lymphadenectomy in patients with localized high risk prostate cancer: comparison of the laparoendoscopic single site (LESS) technique with conventional multiport laparoscopy.

Friedersdorff F, Aghdassi SJ, Magheli A, Richter M, Stephan C, Busch J, Boehmer D, Miller K, Fuller TF.

BMC Urol. 2014 Nov 21;14:92. doi: 10.1186/1471-2490-14-92.

23.

Risk prediction models for biochemical recurrence after radical prostatectomy using prostate-specific antigen and Gleason score.

Hu XH, Cammann H, Meyer HA, Jung K, Lu HB, Leva N, Magheli A, Stephan C, Busch J.

Asian J Androl. 2014 Nov-Dec;16(6):897-901. doi: 10.4103/1008-682X.129940.

24.

Matched comparison of robot-assisted, laparoscopic and open radical prostatectomy regarding pathologic and oncologic outcomes in obese patients.

Busch J, Gonzalgo ML, Leva N, Ferrari M, Cash H, Kempkensteffen C, Hinz S, Miller K, Magheli A.

World J Urol. 2015 Mar;33(3):397-402. doi: 10.1007/s00345-014-1326-1. Epub 2014 May 23.

PMID:
24853030
25.

An epigenetic screen unmasks metallothioneins as putative contributors to renal cell carcinogenesis.

Alkamal I, Ikromov O, Tölle A, Fuller TF, Magheli A, Miller K, Krause H, Kempkensteffen C.

Urol Int. 2015;94(1):99-110. doi: 10.1159/000357282. Epub 2014 Mar 20.

PMID:
24662736
26.

Matched comparison of outcomes following open and minimally invasive radical prostatectomy for high-risk patients.

Busch J, Magheli A, Leva N, Hinz S, Ferrari M, Friedersdorff F, Fuller TF, Miller K, Gonzalgo ML.

World J Urol. 2014 Dec;32(6):1411-6. doi: 10.1007/s00345-014-1270-0. Epub 2014 Mar 9.

PMID:
24609219
27.

Comparison of surgical technique (open vs. laparoscopic) on pathological and long term functional outcomes following radical prostatectomy.

Magheli A, Busch J, Leva N, Schrader M, Deger S, Miller K, Lein M.

BMC Urol. 2014 Feb 7;14:18. doi: 10.1186/1471-2490-14-18.

28.

Functional Epigenetic Analysis of Prostate Carcinoma: A Role for Seryl-tRNA Synthetase?

Ikromov O, Alkamal I, Magheli A, Ratert N, Sendeski M, Miller K, Krause H, Kempkensteffen C.

J Biomark. 2014;2014:362164. doi: 10.1155/2014/362164. Epub 2014 Mar 27.

29.

Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma.

Busch J, Seidel C, Goranova I, Erber B, Peters R, Friedersdorff F, Magheli A, Miller K, Grünwald V, Weikert S.

Eur J Cancer. 2014 Feb;50(3):563-9. doi: 10.1016/j.ejca.2013.10.017. Epub 2013 Nov 13.

PMID:
24239449
30.

Volume matters: CT-based renal cortex volume measurement in the evaluation of living kidney donors.

Halleck F, Diederichs G, Koehlitz T, Slowinski T, Engelken F, Liefeldt L, Friedersdorff F, Fuller TF, Magheli A, Neumayer HH, Budde K, Waiser J.

Transpl Int. 2013 Dec;26(12):1208-16. doi: 10.1111/tri.12195. Epub 2013 Oct 19.

31.

Higher rates of upgrading and upstaging in older patients undergoing radical prostatectomy and qualifying for active surveillance.

Busch J, Magheli A, Leva N, Ferrari M, Kramer J, Klopf C, Kempkensteffen C, Miller K, Brooks JD, Gonzalgo ML.

BJU Int. 2014 Oct;114(4):517-21. doi: 10.1111/bju.12466. Epub 2014 Jan 22.

32.

Pre-operative assessment of living renal transplant donors with state-of-the-art imaging modalities: computed tomography angiography versus magnetic resonance angiography in 118 patients.

Engelken F, Friedersdorff F, Fuller TF, Magheli A, Budde K, Halleck F, Deger S, Liefeldt L, Hamm B, Giessing M, Diederichs G.

World J Urol. 2013 Aug;31(4):983-90. doi: 10.1007/s00345-012-1022-y. Epub 2013 Jan 8.

PMID:
23297099
33.

Retraction: Evaluation of colon cancer-specific antigen 2 as a potential serum marker for colorectal cancer.

Schoen RE, Magheli A, Sokoll LJ, Chan DW, Getzenberg RH.

Clin Cancer Res. 2013 Jan 15;19(2):508. doi: 10.1158/1078-0432.CCR-12-2711. Epub 2012 Dec 27.

34.

Long-term outcomes of living donor kidney transplants in pediatric recipients following laparoscopic vs. open donor nephrectomy.

Chaykovska L, Deger S, Roigas J, Lenz A, Lioudmer P, Kothmann LT, Friedersdorff F, Müller D, Kasper A, Giessing M, Magheli A, Kempkensteffen C, Lingnau A, Fuller TF.

Pediatr Transplant. 2012 Dec;16(8):894-900. doi: 10.1111/petr.12008.

PMID:
23131058
35.

Value of prostate specific antigen density and percent free prostate specific antigen for prostate cancer prognosis.

Busch J, Hamborg K, Meyer HA, Buckendahl J, Magheli A, Lein M, Jung K, Miller K, Stephan C.

J Urol. 2012 Dec;188(6):2165-70. doi: 10.1016/j.juro.2012.07.106. Epub 2012 Oct 18.

PMID:
23083861
36.

Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma.

Busch J, Seidel C, Erber B, Issever AS, Hinz S, Kempkensteffen C, Magheli A, Miller K, Grünwald V, Weikert S.

Eur Urol. 2013 Jul;64(1):62-70. doi: 10.1016/j.eururo.2012.09.004. Epub 2012 Sep 11.

PMID:
22999519
37.

Outcomes after laparoscopic living donor nephrectomy: comparison of two laparoscopic surgeons with different levels of expertise.

Friedersdorff F, Werthemann P, Cash H, Kempkensteffen C, Magheli A, Hinz S, Waiser J, Liefeldt L, Miller K, Deger S, Fuller TF.

BJU Int. 2013 Jan;111(1):95-100. doi: 10.1111/j.1464-410X.2012.11348.x. Epub 2012 Jul 3.

38.

Long-term oncological and continence outcomes after laparoscopic radical prostatectomy: a single-centre experience.

Busch J, Stephan C, Herold A, Erber B, Kempkensteffen C, Hinz S, Lein M, Weikert S, Miller K, Magheli A.

BJU Int. 2012 Dec;110(11 Pt C):E985-90. doi: 10.1111/j.1464-410X.2012.11279.x. Epub 2012 Jun 6.

39.

Laparoscopic and open postchemotherapy retroperitoneal lymph node dissection in patients with advanced testicular cancer--a single center analysis.

Busch J, Magheli A, Erber B, Friedersdorff F, Hoffmann I, Kempkensteffen C, Weikert S, Miller K, Schrader M, Hinz S.

BMC Urol. 2012 May 31;12:15. doi: 10.1186/1471-2490-12-15.

40.

Impact of positive surgical margins on oncological outcome following laparoscopic radical prostatectomy (LRP): long-term results.

Busch J, Stephan C, Klutzny A, Hinz S, Kempkensteffen C, Kilic E, Lein M, Weikert S, Miller K, Magheli A.

World J Urol. 2013 Apr;31(2):395-401. doi: 10.1007/s00345-012-0866-5. Epub 2012 May 11.

PMID:
22576695
41.

Selective lymph node dissection for castration-resistant prostate cancer.

Busch J, Hinz S, Kempkensteffen C, Erber B, Klopf C, Weikert S, Miller K, Magheli A.

Urol Int. 2012;88(4):441-6. doi: 10.1159/000335206. Epub 2012 Mar 7.

PMID:
22398510
42.

Critical analysis of the miniaturized stone basket: effect on deflection and flow rate.

Magheli A, Semins MJ, Allaf ME, Matlaga BR.

J Endourol. 2012 Mar;26(3):275-7. doi: 10.1089/end.2011.0166. Epub 2011 Oct 24.

PMID:
22022885
43.

Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors.

Busch J, Seidel C, Kempkensteffen C, Johannsen M, Wolff I, Hinz S, Magheli A, Miller K, Grünwald V, Weikert S.

Eur Urol. 2011 Dec;60(6):1163-70. doi: 10.1016/j.eururo.2011.07.037. Epub 2011 Jul 21.

PMID:
21802830
44.

Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma.

Busch J, Seidel C, Weikert S, Wolff I, Kempkensteffen C, Weinkauf L, Hinz S, Magheli A, Miller K, Grünwald V.

BMC Cancer. 2011 Jul 14;11:295. doi: 10.1186/1471-2407-11-295.

45.

Impact of fast-track postoperative care on intestinal function, pain, and length of hospital stay after laparoscopic radical prostatectomy.

Magheli A, Knoll N, Lein M, Hinz S, Kempkensteffen C, Gralla O.

J Endourol. 2011 Jul;25(7):1143-7. doi: 10.1089/end.2011.0020.

PMID:
21740262
46.

[Introduction of interdisciplinary prostate cancer centers based on the recommendations of the German Cancer Society. A cost-benefit analysis 3 years after accreditation].

Weikert S, Baumunk D, Stephan C, Cash H, Jahnke K, Steiner U, Werthemann P, Kempkensteffen C, Magheli A, Hinz S, Jagota A, Reichelt U, Busch J, Klopf C, Miller K, Schostak M.

Urologe A. 2011 Sep;50(9):1083-8. doi: 10.1007/s00120-011-2629-0. German.

PMID:
21728009
47.

Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder.

Wang H, Albadine R, Magheli A, Guzzo TJ, Ball MW, Hinz S, Schoenberg MP, Netto GJ, Gonzalgo ML.

Urol Oncol. 2012 Jul-Aug;30(4):428-33. doi: 10.1016/j.urolonc.2010.09.005. Epub 2011 Mar 10.

PMID:
21396836
48.

Intracavitary tumor spread of a metastatic testicular seminoma in the left atrium and ventricle.

Linneweber J, Magheli A, Lembcke A, Christ T, Konertz W.

J Thorac Cardiovasc Surg. 2011 Feb;141(2):583-4. doi: 10.1016/j.jtcvs.2010.09.045. No abstract available.

49.

Significance of preoperative PSA velocity in men with low serum PSA and normal DRE.

Makarov DV, Loeb S, Magheli A, Zhao K, Humphreys E, Gonzalgo ML, Partin AW, Han M.

World J Urol. 2011 Feb;29(1):11-4. doi: 10.1007/s00345-010-0625-4. Epub 2010 Dec 14.

50.

Impact of surgical technique (open vs laparoscopic vs robotic-assisted) on pathological and biochemical outcomes following radical prostatectomy: an analysis using propensity score matching.

Magheli A, Gonzalgo ML, Su LM, Guzzo TJ, Netto G, Humphreys EB, Han M, Partin AW, Pavlovich CP.

BJU Int. 2011 Jun;107(12):1956-62. doi: 10.1111/j.1464-410X.2010.09795.x. Epub 2010 Nov 2.

Supplemental Content

Loading ...
Support Center